pubmed-article:15496649 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C0092777 | lld:lifeskim |
pubmed-article:15496649 | lifeskim:mentions | umls-concept:C1579410 | lld:lifeskim |
pubmed-article:15496649 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:15496649 | pubmed:dateCreated | 2004-10-21 | lld:pubmed |
pubmed-article:15496649 | pubmed:abstractText | The population pharmacokinetics of plasma clofarabine and intracellular clofarabine triphosphate were characterized in pediatric patients with acute leukemias. Traditional model-building techniques with NONMEM were used. Covariates were entered into the base model using a forward selection significance level of .05 and a backwards deletion criterion of .005. Model performance, stability, and influence analysis were assessed using the nonparametric bootstrap and n-1 jackknife. Simulations were used to understand the relationship between important covariates and exposure. A 2-compartment model with weight (scaled to a 40-kg reference patient) modeled as a power function on all pharmacokinetic parameters (0.75 on clearance-related terms and 1.0 on volume-related terms) was fit to plasma clofarabine concentrations (n = 32). White blood cell (WBC) count, modeled as a power function (scaled to a WBC count of 10 x 10(3)/microL), was a significant predictor of central volume with power term 0.128 +/- 0.0314. A reference patient had a systemic clearance of 32.8 L/h (27% between-subject variability [BSV]), a central volume of 115 L (56% BSV), an intercompartmental clearance of 20.5 L/h (27% BSV), and a peripheral volume of 94.5 L (39% BSV). Intracellular clofarabine triphosphate concentrations were modeled using a random intercept model without any covariates. The average predicted concentration was 11.6 +/- 2.62 microM (80% BSV), and although clofarabine triphosphate half-life could not be definitively estimated, its value was taken to be longer than 24 hours. The results confirm that clofarabine should continue being dosed on a per-squaremeter or per-body-weight basis. | lld:pubmed |
pubmed-article:15496649 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15496649 | pubmed:language | eng | lld:pubmed |
pubmed-article:15496649 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15496649 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15496649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15496649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15496649 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15496649 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15496649 | pubmed:month | Nov | lld:pubmed |
pubmed-article:15496649 | pubmed:issn | 0091-2700 | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:GandhiVarshaV | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:PlunkettWilli... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:JehaSimaS | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:CraigAdamA | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:RazzoukBassem... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:WeitmanSteveS | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:BonatePeter... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:GaynonPaulP | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:RyttingMichae... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:SteinherzPete... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:KadotaRichard... | lld:pubmed |
pubmed-article:15496649 | pubmed:author | pubmed-author:LamGilbert... | lld:pubmed |
pubmed-article:15496649 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15496649 | pubmed:volume | 44 | lld:pubmed |
pubmed-article:15496649 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15496649 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15496649 | pubmed:pagination | 1309-22 | lld:pubmed |
pubmed-article:15496649 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:meshHeading | pubmed-meshheading:15496649... | lld:pubmed |
pubmed-article:15496649 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:15496649 | pubmed:articleTitle | Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. | lld:pubmed |
pubmed-article:15496649 | pubmed:affiliation | ILEX Products, 4545 Horizon Hill Boulevard, San Antonio, TX 78229, USA. | lld:pubmed |
pubmed-article:15496649 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15496649 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15496649 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15496649 | lld:pubmed |